Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 07:00 ET | Source: CervoMed Inc.

CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies

FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New Drug Application CervoMed is...
October 28, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley

Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional,...
October 20, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed to Present at the Emerging Growth Conference

BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company),...
October 08, 2025 07:00 ET | Source: CervoMed Inc.

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low...
October 07, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer

BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company),...
October 02, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company),...
September 17, 2025 07:30 ET | Source: CervoMed Inc.

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company),...
September 03, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company...
August 11, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over...
August 05, 2025 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company...